[HTML][HTML] Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID-19

AE Peter, BV Sandeep, BG Rao… - Frontiers in …, 2021 - frontiersin.org
The COVID-19 pandemic has caused a global health crisis, with no specific antiviral to treat
the infection and the absence of a suitable vaccine to prevent it. While some individuals …

Potent anti-SARS-CoV-2 activity by the natural product gallinamide A and analogues via inhibition of cathepsin L

AS Ashhurst, AH Tang, P Fajtová… - Journal of medicinal …, 2021 - ACS Publications
Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a
promising drug target for novel antivirals against SARS-CoV-2. The marine natural product …

[HTML][HTML] COVID-19 vaccines: an overview of different platforms

D Kudlay, A Svistunov - Bioengineering, 2022 - mdpi.com
Vaccination is one of the key strategies to stop the COVID-19 pandemic. This review aims to
evaluate the current state of vaccine development and to determine the issues that merit …

[HTML][HTML] Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face …

M Shen, J Zu, CK Fairley, JA Pagán, L An, Z Du, Y Guo… - Vaccine, 2021 - Elsevier
Background Multiple candidates of COVID-19 vaccines have entered Phase III clinical trials
in the United States (US). There is growing optimism that social distancing restrictions and …

Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA

M Dileepan, D Di, Q Huang, S Ahmed, D Heinrich, H Ly… - Virulence, 2021 - Taylor & Francis
The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is continuing to spread
globally. SARS-CoV-2 infections of feline and canine species have also been reported …

Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies

C Dobaño, R Santano, A Jiménez, M Vidal, J Chi… - Translational …, 2021 - Elsevier
COVID-19 patients elicit strong responses to the nucleocapsid (N) protein of SARS-CoV-2
but binding antibodies are also detected in prepandemic individuals, indicating potential …

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde… - Proceedings of the …, 2021 - National Acad Sciences
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as
the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with …

[PDF][PDF] Prospects of honey in fighting against COVID-19: pharmacological insights and therapeutic promises

KS Hossain, MG Hossain, A Moni, MM Rahman… - Heliyon, 2020 - cell.com
Honey and its compounds are drawing attention as an effective natural therapy because of
its ability to attenuate acute inflammation through enhancing immune response. Several …

COVID-19 vaccination and the eye

MTM Wang, RL Niederer, CNJ McGhee… - American Journal of …, 2022 - Elsevier
Purpose To summarize the current evidence on COVID-19 vaccine-associated ocular
adverse events. Design Narrative literature review. Methods The literature search was …

[HTML][HTML] Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients

AD Moura, HHM da Costa, VA Correa… - Scientific Reports, 2021 - nature.com
SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the
health public in the world. Although there are advances in vaccine development, it is still …